since the cohort will already include a lot of CID patients after first incidence of disease. Therefore, this study will only be able to make a point about CID risk in a population that is already at clearly lower risk of developing some CID. The problem expands, because usually dietry habits do not change much during life. Therefore, the exposure time to the diet is long in 50+ age group and a possible impact of diet is possibly located much earlier in life. I furthermore see a problem in trying a subgroup analysis of different CIDs with relation to the above mentioned, since exposure time to the diet in relation to the max incidence peaks vary greatly when the cut is made at age 50. Therefore, making comparative statements between CIDs is not valid in my opinion, also in case patient numbers are enough to do the subgroup analysis. For the ICD10 codes used, I am a little sceptical about the use of M06 diagnoses, especially M06.9, since this diagnosis is often used for unspecific polyarthritis and more or less not verifiably substitute for "rheumatoid arthritis". Same for M06.1 which is mostly a conglomerate diagnosis of every destructive polyarthritis without serology, which can also include others but "rheumatoid arthritis". On the other hand, all diagnoses related to the group M05 are very specific for seropositive RA. Therefore, the authors should think about renaming the whole group to "chronic polyarthritis, including RA" or at least exclude M06.9.
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GENERAL COMMENTS

General comments
This protocol contains all the necessary information as far as I can judge. The strengths and the weaknesses are appropriately discussed. This seems to be a novel and interesting study. I do not have major comments. Specific comments -Title and elsewhere: 'processed meat': the authors probably mean 'red processed meat' according to the food categories in the FFQ. This is good but it is then probably better to change to 'red meat, red processed meat and fibre…' -Line 342: containing sulphur and sulphate additives? Meat is indeed rich in sulfur-containing amino acids but to my knowledge these are not the cause of the effects of red meat on several chronic diseases. In addition, the level of sulfur-containing amino acids is not much different in white meat or fish compared to red meat. Also, what is meant with sulphate additives? These are not used in meat processing. Please remove the statement between brackets. There must be other hypotheses. Do not confuse with the effect of red meat consumption on sulphate-reducing bacteria in the gut.
- Figure 1 : the abbreviations are not explained in the legend.
VERSION 1 -AUTHOR RESPONSE
Reviewer#1
Reviewer Name: Georg Pongratz 1) The question posed is original and of great value to the field. CID cases are defined by diagnosis from a relevant department and prescription of a drug usually used for the diagnosed disease. Of course, this approach has weaknesses, since there will be always be discussion about the validity of diagnoses. However, in the proposed setting this is the best way to go. Nevertheless, there will be bias for patients with "true" multiple sclerosis, since I assume that to be registered in the multiple sclerosis registry you have to have a specialist confirmed diagnosis upfront, whereas this is probably not the case in the national patients registry for all other CIDs. Maybe the authors should think about analysing the two cohorts separately, or using statistical methods to correct the bias.
Reply: Thank you for this relevant comment. We agree with the reviewer that CID diagnoses found in the Danish National Patient Registry may not all have been confirmed by a medical specialist in contrast to the multiple sclerosis diagnoses from the Danish Multiple Sclerosis Registry which have been confirmed by a medical specialist. This could possibly lead to bias. We agree that analysing the two cohorts separately could be relevant and have added the following to the statistical analysis section:
"Moreover, analyses omitting MS from the overall definition of CID, will be performed." (page 14, line 239-240)
We have also added the column "department with relevant area of specialization" to table 2 to make the definition of the inclusion criteria of the CID outcome clearer (page 9, line 167).
2) A) The second problem with only including patients with diagnosis and typical medication is, that all mild forms, e.g. non-destructive arthritis treated with NSAR only or MS without necessity for treatment will not be included, which also biases the population towards severer cases. Also specificities of medication for different diagnosis are highly variable. E.g. methotrexate for rheumatoid arthritis is very specific, whereas NSAR in the case of spondyloarthropaties are not. Is this somehow accounted for? B) Since the authors use several registries, is there a mechanism necessary to exclude multiple inclusion of the same patient in the dataset?
Reply: 2A) We thank the reviewer for pointing this out. In this study, we have chosen very restrictive criteria for defining the late onset CID cases by requiring that the late onset CID cases fulfill both diagnostic and treatment criteria, or that the cases were registered in the DMSR. This approach ensures that a high proportion of the identified cases really had late onset of CID. Therefore, some "real" CID cases might not have been identified, hence lowering the sensitivity. Furthermore, sensitivity analyses of the outcome variable and use of medication will be carried out (added to page 13, line 231-232).
2 B): All individuals are only included once in the DCH cohort. We have elaborated about the use of the registers and how we ensure the inclusion of the data correct and added:
Data will be linked by the unique identification number assigned to all residents in Denmark at birth or first immigration which provides a unique opportunity to link information about diagnoses, medications, etc. at the individual level. (page 8, line 153 -155).
We are also aware of the possibility that patients can have several CID diagnoses. If that is the case, we will in the overall analyses include the date of the first diagnosis (page 9, line 165 -166).
3) The authors mention themselves, that generalizability is limited due to the inclusion age of greater 50 in the cohort. I personally see a bigger problem there, since most CID has their incidence peak (far) below this age, e.g. spondyloarthritis. This means, that detecting differences in the risk of developing CID is (very) limited, since the cohort will already include a lot of CID patients after first incidence of disease. Therefore, this study will only be able to make a point about CID risk in a population that is already at clearly lower risk of developing some CID. The problem expands, because usually dietary habits do not change much during life. Therefore, the exposure time to the diet is long in 50+ age group and a possible impact of diet is possibly located much earlier in life. I furthermore see a problem in trying a subgroup analysis of different CIDs with relation to the above mentioned, since exposure time to the diet in relation to the max incidence peaks vary greatly when the cut is made at age 50. Therefore, making comparative statements between CIDs is not valid in my opinion, also in case patient numbers are enough to do the subgroup analysis.
Reply: We thank the reviewer for pointing out this very relevant issue regarding the study population' high age at enrolment and the study outcomes. We acknowledge that spondyloarthritis onsets in a younger age (usually before the age of 45 years of age) and have therefore omitted this disease from the study. Furthermore, throughout the manuscript we have changed CID to late onset CID, and in the introduction added:
"Furthermore, one-third of RA patients are diagnosed at >60 years of age and the incidence of lateonset IBD and MS have been reported to increase." (page 4, line 69-71).
Moreover, we have included an analysis among those who at entry to the DCH cohort already had a CID diagnosis to examine if their low/high intake of dietary fibre, red meat and processed meat is associated with having CID. We are well aware that such an analysis might be impacted by bias by indication and that the results should be interpreted with this in mind (page 15, line 274-279).
4) For the ICD10 codes used, I am a little sceptical about the use of M06 diagnoses, especially M06.9, since this diagnosis is often used for unspecific polyarthritis and more or less not verifiably substitutes for "rheumatoid arthritis". Same for M06.1 which is mostly a conglomerate diagnosis of every destructive polyarthritis without serology, which can also include others but "rheumatoid arthritis". On the other hand, all diagnoses related to the group M05 are very specific for seropositive RA. Therefore, the authors should think about renaming the whole group to "chronic polyarthritis, including RA" or at least exclude M06.9.
